Drug Trial Radar · NCT03807063
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Last checked: Nov 19, 2026Latest source record: Aug 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2, 2020
Primary completion
Dec 31, 2020
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Fred Hutchinson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); Bellicum Pharmaceuticals
- First posted
- Jan 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant. Donor T-cell therapy (rivogenlecleucel) may help control transplant-related infections after stem cell transplant.
Conditions
- Acute Bilineal Leukemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Myeloproliferative Neoplasm
- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Myelodysplastic Syndrome
Interventions
RivogenlecleucelBiological
Given IV
RimiducidDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global incidence of grade II-IV acute graft versus host disease (GVHD) requiring rimiducid treatmentTime frame: 1 year after last rivogenlecleucel infusion
- Dose-limiting toxicity (DLT) of BPX-501Time frame: 56 days after last rivogenlecleucel or rimiducid infusion (whichever is later)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.